BHV Partners plans to triple its portfolio and create an investment fund in 2021

BHV Partners accelerates its development plans for 2021. The venture builder specialized in the health sector expects to triple its portfolio next year and participate in up to fifteen companies. The entity currently has four investee companies and seeks to create an investment fund, as explained to PlantaDoce by the CEO of BHV Partners, Marta Príncep. 

If you want to read more about the business plans the company BHV Partners has for 2021, download for free the Born2Invest mobile app. Our companion app brings you the most important business headlines in the world so you can stay on top of the market.

The venture builder has in its portfolio four companies: Aimentia, Nela Biodynamics, Biel Glasses and Match biosystems

Príncep assured that “we are analyzing to enter in a couple of more companies and to have between ten and fifteen in 2021.” The entity has recently entered, together with the venture capital manager Clave, in the capital of Match biosystems, a biotechnology company specialized in developing rapid detection tests for pathogens in clinical and veterinary environments. The objective of BHV Partners, one of the first venture builders specialized in health in Southern Europe, is to grow biomedical companies until they have enough value to be sold to a large group. 

The company was founded at the end of 2018 by Príncep, Albert Zamora, Joaquim Trias and Joan Bigorra, experts in the biomedical sector and health entrepreneurship. BHV Partners has recently entered into the capital of Match biosystems. BHV Partners also plans to create an investment fund in 2021. Príncep pointed out that the platform will have the purpose of financing initial stages. However, the company’s CEO indicates that “the amount of the investment fund is not yet fixed because we are still structuring it.” 

BHV Partners closed a financing round with the support of executives from Ferrer, Uriach and GP Pharm

The venture builder closed its first round of financing of half a million euros last October. Príncep reflects that the operation of BHV Partners got the economic support of executives from Ferrer, Uriach and GP Pharm, as well as entrepreneurs, business angels and medical and scientific experts. So far, the entity has only invested in one of the companies it has in its portfolio, Biel Glasses. The biomedical company is developing intelligent glasses that improve the mobility of people with low vision in order to help them perform in their daily lives with greater autonomy. 

The company recently closed an investment round of $480,000 (€400,000) in which Wavecontrol, a Catalan multinational in the electronics sector, also participated. Biel Glasses will use these funds to manufacture and market the first smart glasses, which it plans to distribute initially in Spain and Denmark. The venture builder also has Aimenta and Nela Biodynamics in its portfolio. The first company is developing an artificial intelligence platform specialized in mental health, while Nela Biodynamics is a start-up specialized in the design and development of orthopedic devices.

__

(Featured image by jarmoluk via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.